This trial is active, not recruiting.

Condition liver dysfunction
Sponsor Boryung Pharmaceutical Co., Ltd
Start date May 2013
End date November 2016
Trial size 601 participants
Trial identifier NCT02385721, BR-FMS-PASS-401


Evaluated the incidence and characteristics of adverse events during the treatment for Kanarb tablet.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Number of Adverse Event
time frame: up to 12 months
Number of Adverse Event, Serious Adverse Event
time frame: up to 12 months

Eligibility Criteria

Male or female participants at least 20 years old.

Inclusion Criteria: - Clinical diagnosis of Hypertension Exclusion Criteria: - Patients with peritoneal dialysis

Additional Information

Official title A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan) During 1 Year Among 20 and Older Diagnosed With Essential Hypertension
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Boryung Pharmaceutical Co., Ltd.